Good MorningEquity markets cheered the FOMC's latest policy shift but should not be sanguine. The Fed's shift is likely short-lived, given the impact of the news on oil and equity markets. The Fed signaled at least three quarter-point interest rate cuts in 2024, clearing the runway for oil and risk-on asset demand. In this environment, inflation could easily accelerate, leading the FOMC to revert to its tighter stance.
The S&P 500 gained more than 1.25% at the height of the session as investors loaded up on deep-value stocks with high yields and a significant chance of outperforming bonds as interest rates fall. Capital invested in such names will continue to pay the same 4% to 6% yield as bonds indefinitely, with the added bonus of capital appreciation.
The bad news is that the technical outlook for the S&P 500 continues to deteriorate. The market moved higher with a solid gain but indicators such as MACD and stochastic are overbought and diverging from the action suggesting growing weakness as the rally grinds higher.
Featured: Move Your Money Here Before August 31st (Ad) 
|
Industrials | |
Dividends are commonly thought of as a reward for long-term investors. Every quarter, certain public companies pay out dividends to their shareholders, who can then use them as income or reinvest them back into the company. But, since company stock only needs to be held for a day for dividend elig... Read the Full Story |
|
From Our Partners | | Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge.
Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks.
Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | | Watch Marc Chaikin's free presentation and get his full buy-and-sell list today |
|
Technology | |
Are you looking for a dividend investing strategy that can help you generate income and grow your portfolio over time? If you are like many investors, you understand the importance of finding top-rated dividend stocks that can provide steady and reliable returns. But with so many options out there... Read the Full Story |
|
Consumer Staples | |
Mastering the art of selecting the right dividend stocks is a top skill set among investors seeking financial prosperity. Learning how to research and find the best dividend-paying stocks becomes crucial as you search for the highest yield stock dividends.
Investing in stocks offering a good div... Read the Full Story |
|
From Our Partners | | Hedge funds are rotating out of AI hype and into the hardware layer powering it. New research identifies three profitable U.S. infrastructure companies leading this shift.
One just posted 76% year-over-year data-center growth. Another holds a $12 billion backlog from global hyperscalers. A third is generating 59%+ gross margins on next-gen chips. | | Access the full analysis, price setups, and catalysts now |
|
Consumer Staples | |
The S&P 500 (NYSE: SPY) is up for the year, but it’s been a tough grind for most. While the broad market is up more than 20% year-to-date, the gains are centered in only two sectors and not all the stocks in those sectors are performing as well. Nine of the eleven sectors are down for th... Read the Full Story |
|
Industrials | |
Being a successful investor takes a lot of discipline, which is genuinely one of the deepest endeavors anyone can take on. Assuming you are not the average investor (you are here, so it's a safe assumption), you understand that a story without numbers is a fairytale and numbers without a story are... Read the Full Story |
|
|
Finance | |
Have you noticed how life has been getting slower lately? Summer and Spring travel is over for the most part, and the end-of-year bug has bitten everyone this month, especially those on Wall Street. The markets are absent for the most part; just take a look at the VIX!
After coming off its 30-35%... Read the Full Story |
|
Consumer Discretionary | |
After being fairly range-bound and placid for the past eighteen months, shares of Domino's Pizza Inc (NYSE: DPZ) are finally starting to break out to the upside. The current rally has been underway since it bounced off a multi-year low last May, with the most recent stage of it having started just... Read the Full Story |
|
Industrials | |
REV Group (NYSE: REVG) struggled to retain and regain traction over the last two years as supply chain hurdles and industry normalization in the RV market took a toll on production and deliveries. However, the company leaned hard into the supply chain and operating improvements that began to take ... Read the Full Story |
|
Technology | |
Oracle (NYSE: ORCL) had a weaker-than-expected FQ2 relative to analysts' expectations, but the outlook is as robust as ever. The biggest takeaway from the report is that weakness was caused by insufficient capacity, and capacity is ramping. The news for investors is that Oracle will continue to gr... Read the Full Story |
|
Technology | |
Advanced Micro Devices (NASDAQ: AMD) investor day event did not spark a serious change in the analysts' outlook, but it did paint a rosy picture of the company’s future. The takeaway is that the accelerator market is still in the discovery phase, getting bigger with every estimate and Advanc... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California. | | View Today's Stock Pick |
|
